{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-111832","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2023-04-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.334850+00:00","generated_at":"2026-06-16T19:10:27.164866+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IN8bio reports 100% complete remission in INB-100 Phase 1 leukemia trial; RP2D selected","bullets":["100% of evaluable patients (n=7) in durable CR; one patient progression-free beyond 3 years.","Gamma-delta T cells expanded 82.9x at Dose Level 2 vs. standard haploidentical HSCT at 60 days.","Dose Level 2 selected as recommended Phase 2 dose based on safety, tolerability, and expansion data.","No dose-limiting toxicities observed; all GvHD low-grade and steroid-responsive.","Conference call today at 10 a.m. ET; updated data expected at future medical meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-111832","json":"https://secwatch.observer/filing/0001193125-23-111832.json","markdown":"https://secwatch.observer/filing/0001193125-23-111832.md","text":"https://secwatch.observer/filing/0001193125-23-111832.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523111832/0001193125-23-111832-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312523111832/d421859d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T19:10:27.164866+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}